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Background: HIV-l reverse transcriptase (RT) is a
multifunctional enzyme that copies the RNA genome of
HIV-1 into DNA. It is a heterodimer composed of a
66 kDa (p66) and a 51 kDa (p51) subunit. HIV-I RT is a
crucial target for structure-based drug design, and potent
inhibitors have been identified, whose efficacy, however,
is limited by drug resistance.
Results: The crystal structure of HIV-1 RT in complex
with the non-nucleoside inhibitor xt-anilinophenyl-
acetamide (-APA) R95845 has been determined at
2.8 A resolution. The inhibitor binds in a hydrophobic
pocket near the polymerase active site. The pocket con-
tains five aromatic amino acid residues and the interac-
tions of the side chains of these residues with the aromatic
rings of non-nucleoside inhibitors appear to be important
for inhibitor binding. Most of the amino acid residues
where mutations have been correlated with high levels of
resistance to non-nucleoside inhibitors of HIV-1 RT are
located close to a-APA. The overall fold of HIV-I RT in
complex with et-APA is similar to that found when in
complex with nevirapine, another non-nucleoside inhib-
itor, but there are significant confonnational changes rela-
tive to an HIV-1 RT/DNA/Fab complex.
Conclusions: The non-nucleoside inhibitor-binding
pocket has a flexible structure whose mobility may be
required for effective polymerization, and may be part of
a hinge that permits relative movements of two sub-
domains of the p66 subunit denoted the 'palm' and
'thumb'. An understanding of the structure of the
inhibitor-binding pocket, of the interactions between
HIV-1 RT and a-APA, and of the locations of mutations
that confer resistance to inhibitors provides a basis for
structure-based design of chemotherapeutic agents for the
treatment of AIDS.
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Introduction
Human immunodeficiency virus type I (HIV-1) is the
causative agent of AIDS. HIV-1 reverse transcriptase
(RT) is responsible for the transformation of the single-
stranded RNA genome of HIV-1 into the linear double-
stranded (ds) DNA that becomes permanently integrated
into the chromosomes of the host cells. RT is the thera-
peutic target of many of the agents that inhibit replica-
tion of HIV-1 and has been the subject of extensive
scientific studies (reviewed in [1-31). Currently, two
functionally distinct classes of HIV-1 RT inhibitors have
been discovered and are being used clinically or are in
clinical trials [3,4]. The first of these, the nucleoside ana-
log inhibitors, are analogs of normal deoxynucleoside
triphosphates (dNTPs). The only drugs now used for the
treatment of AIDS patients, 3'-azido-3'-deoxythymidine
(AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine
(ddC), and 2',3'-didehydro-2',3'-dideoxythymidine (d4T)
are nucleoside analogs. However, nucleoside analogs are
not specific for HIV-1 RT, and are incorporated into cel-
lular DNA by the host DNA polymerases and can there-
fore cause serious side effects. Moreover, treatment with
these analogs leads to the emergence of drug-resistant
viral strains that contain mutations in HIV- RT
(reviewed in [3-5]). The other class of HIV-1 RT
inhibitors, known as non-nucleoside inhibitors, include
tetrahydroimidazo(4,5, 1-1 -jk) ( ,4)-benzodiazepin-2(1 H)-
one and -thione (TIBO) derivatives [6], dipyridodiaze-
pinones [7], pyridinones 181, bis(heteroaryl)piperazines
(BHAPs) [9], and 2',5'-bis-O-(tertbutyldimethylsilyl)-3'-
spiro-5"-(4"-amino- 1 ",2"-oxathiole-2",2"-dioxide)pyri-
midine (TSAO) derivatives [101 (reviewed in [3,11]).
The x-anilinophenylacetamide (-APA) compounds
(Fig. 1) were developed at Janssen Research Foundation
[12] and represent an additional class of highly potent and
specific non-nucleoside inhibitors. The dichlorinated
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compound Ot-APA R90385 has an IC 50 (50% inhibitory
concentration in MT-4 cells) of 5 nM and a selectivity
index (50% cytotoxic concentration/50% inhibitory con-
centration) of 84000. In addition, these compounds are
chemically simple and economical to synthesize, exhibit-
ing potential for bulk production and rapid development
of new analogs [12]. R89439 (the racemic mixture of
R90385 and its enantiomer), which has been named
Loviride, is currently being tested in clinical trials in
AIDS patients and has been shown to induce a prolonged
rise in the CD4 count in asymptomatic HIV-1 positive
patients (M De Brabander, et al., & PA Janssen, abstract
PB0242, p. 203, The Tenth International Conference on
AIDS, Japan, August, 1994; S Staszewski, et al., & R Van
Den Broeck, abstract 513B, p. 59, The Tenth Interna-
tional Conference on AIDS, Japan, August, 1994). In
contrast to nucleoside analogs, non-nucleoside inhibitors
are highly specific for HIV-1 RT and do not inhibit
either HIV-2 RT or normal cellular polymerases, thus
exhibiting lower cytotoxicity and fewer side effects.
However, non-nucleoside inhibitors also induce the
emergence of resistant strains of virus [3,5,12,13]. Multi-
drug combination therapy has been tried, but drug-resis-
tant viral strains still emerge [14].
Fig. 1. Chemical structure of a-anilinophenylacetamide, aY-APA.
In the analog R 95845, X=Br and in R 90385, X=CI. The asterisk
denotes the location of the chiral carbon atom which has the S
configuration in both R 95845 and R 90385.
HIV-1 RT is a heterodimer that contains two related
polypeptides of 66 kDa (p66) and 51 kDa (p51). The
polymerase domain of HIV-1 RT comprises the N-termi-
nal 440 amino acid residues of the p66 subunit. The ribo-
nuclease H (RNaseH) domain comprises the remaining
120 amino acid residues at the C terminus of p66. The
p51 subunit, which is proteolytically derived from p66 or
from some larger precursor, has the same amino acid
sequence as the polymerase domain of p66. The poly-
merase domains of both p66 and p51 contain four sub-
domains, denoted fingers, palm, thumb and connection
[15]. The overall fold of individual subdomains is similar
in both subunits. However, the relative spatial arrange-
ment of the subdomains in the two subunits is surprisingly
different. In the p66 subunit, the fingers, palm and thumb
subdomains form a large cleft that accommodates the
template-primer dsDNA [16]. The trio of aspartic acid
residues (110, 185 and 186) that is strictly conserved in
retroviral RTs and forms part of the polymerase active
site, lies on the 'floor' of this binding cleft.
The three-dimensional structure of HIV-1 RT has been
determined by X-ray crystallography in a complex with
the non-nucleoside inhibitor nevirapine [15,17] and in a
ternary complex with a 19-mer/18-mer dsDNA tem-
plate-primer and the Fab of a monoclonal antibody
(HIV-1 RT/DNA/Fab) [16] (reviewed in [18]). The
structure of HIV-1 RT in the absence of inhibitor or
template-primer was also described (R Raag, et al., & E
Arnold, abstract B03, p. 44, American Crystallographic
Association Meeting, Atlanta, June, 1994; [19,20]). The
structure of a truncated version of HIV-1 RT corre-
sponding to the fingers and palm subdomains has been
reported at 2.2 A resolution [21].
Here we report the crystal structure of HIV-1 RT in a
complex with the non-nucleoside inhibitor Oa-APA
R95845 (the dibrominated form of ot-APA R90385) at
2.8 A resolution and the interactions between the bound
inhibitor and the amino acid residues forming the
inhibitor-binding pocket. There are significant differ-
ences in the structures of HIV-1 RT/o-APA and HIV-1
RT/DNA/Fab complexes. The potential functional
implications of these differences are discussed.
Results and discussion
Summary of the structure determination and refinement
In the following discussion, RT will be used to refer to
HIV-1 RT unless otherwise specified. A summary of the
crystallographic data is given in Table 1. The initial phas-
ing was determined using the molecular replacement
(MR) method as implemented in the program X-PLOR
[22]. The starting model was a polyalanine model of RT,
built on the basis of the coordinates from the
RT/DNA/Fab complex ([16]; J Ding et al., unpublished
data), using the partial Cot model of the RT/nevirapine
complex [15] as a guide. The MR phasing was supple-
mented by multiple isomorphous replacement (MIR)
phasing, solvent flattening, phase extensions, and iterative
combination of partial model and MIR phases.
Electron-density map averaging from multiple crystal
forms of RT/non-nucleoside inhibitor complexes
yielded the most reliable maps for model building. The
location of ot-APA was determined using the difference
Fourier method. The orientation and conformation of
a-APA was interpreted on the basis of the difference
Fourier (Fo-Fc) maps and the difference Fourier electron
density between the RT/R 95845 complex and the
RT/R90385 complex, where R95845 and R90385 are
dibrominated and dichlorinated analogs of ao-APA,
respectively (Fig. 2a). Molecular modeling was carried
out iteratively using the graphics program 'O' [23]. The
structure refinement was performed using conventional
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positional refinement and the simulated annealing proto-
col within X-PLOR [22]. The statistics of model refine-
ment are summarized in Table 2.
Overall structure of the HIV-1 RT p66/p51 heterodimer
Fig. 2b shows a representative portion of a 2 mFo-Fc
(SIGMAA-weighted [24,25]) difference Fourier map at
2.8 A resolution in the region around the non-nucleoside
inhibitor-binding pocket. Overall, the electron density
for most of the amino acid residues and the inhibitor was
clearly defined. The structure of the RT/ox-APA com-
plex is shown in Fig. 3. Most of the p66/p51 hetero-
dimer in the RT/ot-APA complex has the same
secondary-structure assignment as was given for the
RT/DNA/Fab complex (Fig. 2 of [16]). As in the
RT/nevirapine and RT/DNA/Fab structures, the poly-
merase domain of the p66 subunit resembles a right hand
and the fingers, palm, and thumb subdomains form a
cleft that can accommodate the template-primer sub-
strate [15,16]. The thumb subdomain of p66 in the
RT/ot-APA structure is not folded down into the DNA-
binding cleft as it is in the RT structures lacking bound
inhibitor or DNA (R Raag, et al., & E Arnold, abstract
B03, p. 44, American Crystallographic Association
Meeting, Atlanta, June, 1994; [20]); instead, it is in an
upright position. This position is similar to that of the
p66 thumb in the RT/nevirapine and RT/DNA/Fab
structures, suggesting that both non-nucleoside inhibitors
and nucleic acid template-primers influence the position
of the thumb. As in the RT/DNA/Fab and the
RT/nevirapine structures, the p66/p51 heterodimer
interface is primarily formed by interactions in three
regions: first, between the p66 palm (residues 85-90,
93-96, 99-100 and 161-162) and the p51 fingers
(residues 52-57, 131, 136-137, 140 and 143) subdo-
mains; second, between the p66 connection (residues
381-384, 402 and 405-410) and the p51 connection
(residues 331, 364-365, 392-394, 397, 401, 405 and
417-419) and fingers (27-28 and 136-137) subdomains;
Fig. 2. (a) Stereoview of difference
Fourier maps showing the fit of ct-APA
into the electron density. The a-APA
coordinates correspond to the current
refined model. The green map is the dif-
ference Fourier map at 3.5 A resolution
between the HIV-1 RT/a-APA R 95845
(dibrominated) complex and the HIV-1
RT/c-APA R 90385 (dichlorinated) com-
plex contoured at a 10cr level which
revealed the positions of two bromine
atoms. The blue map is the mFo-Fc dif-
ference Fourier map at 3.0 A resolution
calculated from a model before ac-APA
was included in the refinement; the
phases were computed from the back-
transformation of electron density aver-
aged from three HIV-1 RT/inhibitor
complexes; the map is contoured at
1.5o. (b) Stereoview of a portion of a
2mFo-Fc difference Fourier map at 2.8 A
resolution in the region around the non-
nucleoside inhibitor-binding pocket
showing the cs-APA inhibitor and some
of the nearby amino acid residues. The
phases were computed from the current
atomic model (R=0.255) and the map is
contoured at 1.2r.
Table 1. Summary of crystallographic data.
Native Native
Dataset (R 95845) Hg-dUTP TAMM (R 90385)
No. of crystals 15 7 14 11
No: of images 136 47 65 84
Resolution (A) 2.6 3.0 3.0 2.6
Unique reflectionsa 37099 13524 21 615 34168
Observed reflections 113 074 37 642 48 594 91 341
Completeness (%) 78 41 67 71
Rmergeb 0.10 0.14 0.11 0.11
Rderiv 0.37 0.34
Phasing powerd 1.84 1.64
Rcentric e 0.76 0.69
FOMf 0.32 0.34
Abbreviations: Hg-dUTP, 5-mercurideoxyundine 5'-triphosphate; TAMM,
tetrakis(acetoxymerucuri)methane. aThe reflections listed here have 1i>2(1);
in multiple isomorphous replacement (MIR) phase calculations and struc-
ture refinement, we used reflections with F3(F). bRme,rge = l 1obs
- <> /<1 >
CRderiv=5 I'PH-Ipj/yIp. dPhasing power= [ IFH12/Z(IFpHobS-IFPHC,,lc)21.
eRcentric=zIIFPH± FPI-FHVIIFpH-FI -fThe overall MIR figure of merit (FOM)
is 0.40 for 21 810 reflections to 3.OA resolution [F3a(F)] and 0.81 after it-
erative solvent flattening (see the Materials and methods section).
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Table 2. Statistics of model refinement.
Resolution range 10.0-2.8 A
No. of reflections 31 444 (working set: 30186; test set: 1258)
Completeness 81.8% (working set: 78.5%; test set: 3.3%)
R-factor a 0.255
Free R-factor 0.360
Number of:
protein residues 985 (p66: 1-558; p51: 1-427)
protein non-H atoms 7792 (p66: 4368; p51: 3424)
inhibitor non-H atoms 23
Averaged B-factor 39A 2 (p66: 43A2, p51: 34A 2 )
Rms bond lengths 0.014 A
Rms bond angles 0.81°
Rms dihedral angles 25.24 °
Rms improper angles 1.64°
aR = II Fobs-I Fca lcl/l Fobl.
and third, between the RNase H (residues 432-436,
439-441, 459, 500, 532, 536 and 541-546) and the p51
thumb (residues 255, 258-259 and 280-290) and con-
nection (residues 421-422) subdomains (Fig. 3) [26,27].
Location of the oa-APA inhibitor and nature of the non-
nucleoside inhibitor-binding pocket
The ot-APA inhibitor is located in the core of a highly
hydrophobic pocket, referred to as the non-nucleoside
inhibitor-binding pocket, composed primarily of amino
acids from secondary-structure elements of the p66 palm
subdomain: the [35b-[36 loop (Pro95, LeulOO, LyslO1
and LyslO03), [36 (Val106 and VallO8), the [39-[310 hair-
pin (Val179, Tyrl81, Tyr188 and Gly190), and the
[312-[13 hairpin (Phe227, Trp229, Leu234 and Pro236),
as well as 15 (Tyr318) from the p66 thumb subdomain
(Fig. 4). The pocket lies near, but is distinct from, the
polymerase active site which contains the highly con-
served Tyr-Met-Asp-Asp (YMDD) motif at positions
183-186. A possible solvent-accessible entrance to the
pocket is located at the p66/p51 heterodimer interface
and the residues at the rim of the putative entrance are
LeulOO, LyslOl, LyslO03, Va1179 and Tyrl81 of p66, and
Glu138 of the [37-[38 loop of the p51 fingers (Fig. 4).
Most of the amino acid residues that form the binding
pocket are hydrophobic and five of them have aromatic
side chains. The only hydrophilic residues around the
pocket (Lysll101 and Lys103 of p66, and Glu138 of p51)
are located at the putative entrance. The potential roles
of these residues are not yet clear but all confer resistance
to non-nucleoside inhibitors when mutated (see below).
It is conceivable that their flexible and polar side chains
may act to recognize molecules that are trying to enter
the pocket and/or to prevent the bound inhibitor escap-
ing from the pocket.
Only one non-nucleoside inhibitor-binding site is found
in the p66 /p51 heterodimer [15]. Relative to the p66
subunit, the thumb subdomain of p51 is rotated away
from the DNA-binding cleft and the connection subdo-
main is folded up onto the palm between the fingers and
thumb. The region of p51 corresponding to the
[312-[13-[314 sheet of p66, which forms an important
part of the binding pocket, is completely unraveled and
extended in the RT/a-APA structure. The movement of
the thumb also correlates with the movement of [315.
Interactions of the a-APA inhibitor with specific amino acid
residues
Table 3 lists the interactions between ot-APA and the sur-
rounding amino acid residues. Because of the hydropho-
bic nature of the non-nucleoside inhibitor-binding
pocket and the inhibitor, most of the close contacts
between c-APA and the surrounding residues are
hydrophobic interactions. There are 43 protein-inhibitor
interactions with a distance of <3.6 A, two of which are
potential hydrogen-bonding interactions between the
amide group of ot-APA and the carbonyl groups of amino
acid residues Tyr188 (Tyr188 O...N8B ot-APA, 2.8 A)
and Va1189 (Val1189 O...N8B o-APA, 3.2 A) (Table 3).
The non-nucleoside inhibitors are a diverse class of com-
pounds with different chemical structures, but they are all
hydrophobic and contain aromatic groups. We proposed
that interactions between the aromatic rings of inhibitors
and the aromatic side chains of Tyrl81, Tyr188 and other
residues in the binding pocket would be important for the
binding of most non-nucleoside inhibitors [18]. Analysis
of the inhibitor-protein interactions shows that the two
Fig. 3. Stereo Ca trace of the HIV-1 RT
p66/p51 heterodimer in complex with
a-APA showing the overall structure, the
heterodimer interface, the location of
the polymerase active site, and the loca-
tion of the non-nucleoside inhibitor-
binding pocket. The p66 and p51
subunits are drawn in solid and dashed
lines,respectively. The bound inhibitor is
shown as a ball-and-stick model and the
three aspartic acids at the polymerase
active site are shown as open circles.
Every 50th residue is labeled: p66,
1-558 and p51, 1001-1427. The subdo-
mains are colored as: fingers, blue;
palm, red; thumb, green; connection,
yellow; and RNase H, magenta. (Figure
generated using MOLSCRIPT 164].)
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Fig. 4. Close-up of the non-nucleoside
inhibitor-binding pocket in the structure
of the HIV-1 RT/a-APA complex looking
through a putative entrance to the
pocket, showing interactions between
ot-APA and nearby amino acid residues.
a-APA is shown in purple as a ball-and-
stick model with carbons purple, nitro-
gens cyan, oxygens red and bromines
magenta. The 137-P8 portion of p51 has
a dashed outline. The side chains are
shown for the amino acid residues that
make close contacts with a-APA (in
green), and for the three essential aspar-
tic acid residues D 110, Di185 and DI186
(in red) at the polymerase active site.
Dashed lines indicate connections
between the side chains and the
p-strands.
aromatic rings of ot-APA have potentially significant aro-
matic-aromatic interactions with the aromatic amino acid
residues in the pocket (Table 4). The centroid-to-centroid
distances are within the energetically favorable range
(3.9-6.8 A) commonly observed in protein structures
[28]. As expected, the aromatic-aromatic interactions in
the current structure (listed in Table 4) are either of the
favorable edge-to-face (tilted T) or of the favorable offset
stacked (parallel displaced) types [29] (Fig. 4). Interactions
among the aromatic side chains of the amino acid residues
forming the pocket could influence the structure of the
pocket and could help explain the phenotypic conse-
quences of some of the mutations that confer resistance to
non-nucleoside inhibitors (see below).
Non-nucleoside inhibitor-resistant mutations are located
close to the bound inhibitor: implication for mechanisms of
resistance to non-nucleoside inhibitors
Most of the non-nucleoside inhibitor-resistant mutation
sites that have been reported (for example, Ala98,
Leu100, LyslOl, Lysl03, Vall106, Val108, Glu138,
Val179, Tyrl81, Tyr188, Gly190 and Pro236) map to
amino acid residues that are located close to the bound
ot-APA inhibitor (Fig. 4). The shortest distances between
the ot-APA R95845 and the residues whose mutation
confers resistance to non-nucleoside inhibitors are also
given in Table 3. With the exception of Ala98 and
Val108, each of the commonly identified non-nucleoside
inhibitor-resistant mutations in the p66 subunit has a
contact at a distance of -4 A or less.
The nature of the mutations that cause resistance varies
and the potential mechanism of resistance will depend on
the specific amino acid change. Pauwels et al. [12]
reported that the mutation Leu100-->Ile in HIV-1 RT
caused an approximately three-fold drop in sensitivity of
HIV-1 to o-APA R89439. This moderate resistance may
be due to a mild steric conflict with the inhibitor, as the
side chain of Leu100 makes a close contact with the
bound oa-APA (Table 3). Changes at position 181, in
which the tyrosine is mutated to cysteine or isoleucine,
have much more dramatic consequences [12]. A viral
variant that contains the Tyrl81->Cys mutation, which
has been identified as causing high-level resistance to
nearly all non-nucleoside inhibitors [5,30], has >4000-
fold resistance to R89439 in cell culture. In addition,
recombinant HIV-1 RTs that contain Tyrl81-Cys or
Tyrl81--Ile mutations show a dramatic loss of sensitivity
to inhibition b o-APA R89439 [12]. The loss of the
aromatic side chain at residue 181 could cause a signifi-
cant reduction in the favorable aromatic ring interactions.
For example, TyrI81 has aromatic-aromatic interactions
with ao-APA, the side chains of Tyrl88 and Trp229 (both
of which are also involved in the aromatic cluster with
a-APA), and the side chain of Tyr183, hence, mutation of
TyrI81 may influence the conformations of the inhibitor
and these amino acid residues. In addition, because
Tyr181 is located at what may serve as an entrance to the
pocket (Fig. 4), the mutations Tyr8l81--->Cys and
Tyrl81->Ile eliminate aromatic-aromatic interactions
with non-nucleoside inhibitors that could help 'steer' the
compounds into the pocket. The importance of the inter-
action between Tyr188 and oa-APA is supported by the
observation that recombinant HIV-1 RT containing a
Tyrl88--Leu mutation is >1000-fold more resistant to
R89439 than is wild-type HIV-1 RT [12]. The aromatic
ring of Tyr188 has stabilizing interactions with aromatic
moieties of ot-APA, Tyrl81 and Phe227 (Table 4). The
importance of having aromatic side chains at both Tyrl81
and Tyr188 for binding of non-nucleoside inhibitors is
also supported by site-directed mutagenesis studies show-
ing that HIV-1 RT with tryptophan or phenylalanine at
these positions shows little or no resistance to non-nucle-
oside inhibitors [31]. Most of the other non-nucleoside
inhibitor-resistant mutation sites are also located close
enough to the bound inhibitor that changes in these
residues are likely to affect the shape of the inhibitor-
binding pocket. Some of the additional mechanisms may
include increased side-chain bulk leading to steric conflict
(for example, Vall108-Ile, Va179--Asp, Va1179-->Glu,
Glyl90O-Glu and Pro236--->Leu), loss of contact (for
example, LyslO3--Asn and VallO6--Ala), or the change
of local charge or electrostatic potential (for example,
LyslOl0-Glu, Lys103-4Asn, Vall79--Asp, Va1179---Glu
and Glyl90-4Glu). Ala98 and Val108 are located 8.7 A
and 5.9 A away from the e(-APA inhibitor, respectively.
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Table 3. Interactions or shortest distances (in A) between a-APA R95845
and amino acid residues in the non-nucleoside inhibitor-binding pocket, at
the polymerase active site, and at the non-nucleoside inhibitor-resistant
mutation sites.
Residue Atom a-APA Distance Mutation Location Reference
Pro95 Cp C2
Pro97 Ca C2
Ala98 N C2
Leul00 C81 C1
LyslOl O C13
Lysl 03 Cy Br2
Val106 Cyl N8B
Cyl Brl
Val108 Cy2 Brl
Va1179 O 088
Cp 08B
Cyl O1 B
Tyr 181 Cp C1
Cp CIA
Cy Cl
Cy C1A
Cy C2
C81 C1 B
C82 C1
C82 C2
C82 C3
C82 C4
CE2 C2
C£2 C3
Tyrl 88 C N8B
O N88
O C8A
Cp N88
C82 C4A
CE2 C4A
Val1189 C N8B
O N8B
Gly190 N N8B
Ca N8B
Ca 088
Phe227 C52 Brl
Trp229 C C4A
Cy C4A
C82 C3
C82 C4A
CE2 C3
C£2 C4A
C£3 C3
C£3 C4A
CC2 C3
Cr3 C3
C2 C3
Leu234 Cl1 Brl
Pro236 Ca C12
Tyr318 C£2 C12
Cc2 C13
Glul38 (p51) Cy C1B
Asp110c N N8B
Asp185c C C4A
Asp186C Cp C4A
4.5a
6.5 a
8.7 a
3.6
3.5
3.8a
3.2
3.6
5.9a
3.4
3.6
3.6
3.6
3.6
3.4
3.6
3.3
3.5
3.5
3.1
3.1
3.6
3.3
3.1
3.1
2.8 b
3.5
3.3
3.6
3.3
3.2
3.2b
3.3
3.5
3.6
4.2a
3.6
3.1
3.6
3.0
3.4
3.5
3.6
3.3
3.2
3.4
3.2
4.0 a
4.3a
3.0
3.6
4.0 a
11.2a
10.4a
7.0 a
Ala-4Gly
Leu--lle
Lys-sGlu
Lys-Asn
Val->Ala
Val--lle
Vale-Asp
Val-Glu
Tyr-Cys
55b
S5b-p6
P5b-p6
p5b-6
P5b-P6
55b-P6
16
P6
P9
P9
[30]
[58-60]
133]
[13,60]
[59]
[581
130]
[30]
[13,61]
Tyr-His p10 [60]
O10
Gly~-Glu 10 [5,39,62]
512
p12
113
Pro--Leu p13-p14 [63]
P15
Glu--Lys 57-P8
P6
19-10
59-pl10
160o
aThe shortest distances of any atom pair is given for these residues. bThese
atoms have potential hydrogen-bonding interactions, cThese three aspartic
acid residues are at the polymerase active site.
Mutations at these sites probably affect the conformation
of nearby residues that interact directly with the inhibitor.
As p51 is a proteolytic product of p66, any mutations that
give rise to drug resistance are present in both subunits. It
was predicted, based on the structure of HIV-1 RT, that
most of the mutations that confer resistance to non-
nucleoside inhibitors will act through the change in the
p66 subunit. The exception is the mutation Glu138--Iys
which was predicted to act through the change in p51
[18]. Subunit-specific mutagenesis has been used to con-
firm the prediction: resistance to TSAO and TIBO com-
pounds occurs only with the Glu138--->Lys change in the
p51 subunit and not in the p66 subunit, whereas most
other mutations confer resistance only when present in
the p66 subunit [32,33]. In the p66 subunit, Glu138 of
the 37-[38 connecting loop is located on the outer sur-
face of the heterodimer, far away from the non-nucleo-
side inhibitor-binding pocket. However, Glu138 of p51
is located at the putative entrance to the non-nucleoside
binding pocket. Although Glu138 of p51 has no direct
contact with the inhibitor in this structure, its side chain
approaches the inhibitor (Glu138 Cy. ..C1B ao-APA,
4.0 A) and the side chain of Tyrl81 (Glu138 O...CEl
Tyrl81, 3.8 A) quite closely. These interactions may
affect the precise position of ox-APA and the side-chain
orientation of Tyrl81.
Non-nucleoside inhibitors vary widely in chemical struc-
ture and some of the compounds, such as TSAO and
BHAP derivatives, are substantially larger than the o-APA
compounds. It is likely that different non-nucleoside
inhibitors contact different portions of the binding pocket
and have the potential for interacting with different sets
of RT amino acid residues, which would account for the
varying spectra of inhibitory activity and resistance.
Analysis of amino acid residues in the non-nucleoside
inhibitor-binding pocket of HIV-2 RT and SIV RT
The non-nucleoside inhibitors are highly specific for
HIV-1 RT and have little or no inhibitory activity against
a variety of other viral and cellular polymerases tested
[6-9,34,35], including the closely related HIV-2 RT and
simian immunodeficiency virus (SIV) RT. Sequence
Table 4. Centroid-to-centroid distances for pairs of aromatic rings that
have potential aromatic-aromatic interactions in the non-nucleoside
inhibitor-binding pocket.
Aromatic Aromatic Centroid-to-centroid Shortest C-C Interaction
ring 1 ring 2 distance (A) distance (A) type
a-APA ring la Tyrl81 3.9 3.1 Offset stacked
Tyrl 88 5.4 3.7 Edge-to-face
Trp229 4.4b 3.2 Edge-to-face
a-APA ring 2a Tyr318 5.5 3.0 Offset stacked
Tyrl81 Tyr183 6.4 4.2 Offset stacked
Tyrl 88 6.8 5.0 Edge-to-face
Trp229 5.8b 4.0 Edge-to-face
Tyrl 83 Trp229 6.6b 5.2C Edge-to-face
Tyrl 88 Phe227 6.3 4.6 Edge-to-face
Trp229 Tyr232 5.6 4.2 Offset stacked
Tyr232 Trp239 5.8b 3.7 Edge-to-face
aRing 1 of a-APA is composed of C1-C6; ring 2 is composed of C9-C14.
bOnly the six-membered rings of Trp229 and Trp239 were included in the
centroid-to-centroid distance calculation. cAlthough the centroid-to-centroid
distances for these aromatic pairs are <7 A [28], the shortest C-C distance is
>4.8A [29] and these interactions will be weaker.
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alignment of HIV-1 RT and HIV-2 RT, which have an
overall amino acid sequence identity of -60%, demon-
strates that the two enzymes have a number of amino
acid differences in the region of the non-nucleoside
inhibitor-binding pocket (Fig. 5). A series of studies
using chimeric HIV-1/HIV-2 RT enzymes indicated that
several regions of the RT sequence were involved in
non-nucleoside inhibitor binding [36-38]. It was shown
that the region 176-190, which forms part of the pocket,
was especially important in conferring sensitivity to non-
nucleoside inhibitors. Site-directed mutagenesis studies
of HIV-1 RT and HIV-2 RT have underscored the
important roles of Tyrl81 and Tyrl88 in binding of non-
nucleoside inhibitors [36,37]. HIV-2 RT has isoleucine
and leucine residues at positions 181 and 188, respec-
tively. Therefore, the energetically favorable aromatic-
aromatic interactions observed between these residues in
HIV-1 RT and the inhibitor are lost. Additional differ-
ences in the pocket residues occur at positions 101, 106,
179, 190 and 227 (Fig. 5). Mutations at residues 179 and
190 confer resistance to some non-nucleoside inhibitors
[39,40]. Residues 101 and 106 have been identified as
drug-resistant mutation sites and were found to be crucial
for enzymatic activity [37,39,40]. The amino acid differ-
ences at these positions may contribute to the lack of
sensitivity of HIV-2 RT to non-nucleoside inhibitors.
SIVs are a family of primate viruses that are related to
HIV-1 [41]. Sequence comparisons indicated that
SIVmac and SIVsm [42] strains are very closely related to
Fig. 5. Sequence alignment of amino
acid residues from HIV-1, HIV-2, and
simian immunodeficiency virus (SIV)
RTs in the regions that form the non-
nucleoside inhibitor-binding pocket.
Residues forming part of the pocket are
boxed. Residues whose mutations con-
fer drug resistance are underlined. The
YMDD motif and Asp110, which are
essential for polymerase catalytic activ-
ity, are shown in bold italicized text.
The secondary-structure assignment for
HIV-1 RT is indicated [16]. The
sequences displayed are: HIV-1 RT
(strain LAI) 65]; SVcpz RT [43]; HIV-2
RT (strain ROD) [66]; SIVmac RT (strain
251) [67]; SIVagm RT (strain 3) [68];
and SIVmnd RT (strain GB-1) [69].
HIV-1 RT
SIVcpz RT
HIV-2 RT
SIVmac RT
SIVagm RT
SIVmnd RT
HIV-1 RT
SIVcpz RT
HIV-2 RT
SIVmac RT
SIVagm RT
SIVmnd RT
HIV-1 RT
SIVcpz RT
HIV-2 RT
SIVmac RT
SIVagm RT
SIVmnd RT
HIV-1 RT
SIVcpz RT
HIV-2 RT
SIVmac RT
SIVagm RT
SIVmnd RT
<- 05b ->
93 95
GI PH
* * * 0
HIV-2, whereas SIVagm and SIVmnd strains are more
divergent [41,43,44]. The amino acid sequences of the
RTs of SIVmac and HIV-2 are quite similar in the region
that forms the non-nucleoside inhibitor-binding pocket
of HIV-1 RT (Fig. 5), which explains the failure of non-
nucleoside inhibitors to block SIVmac251 replication
[7,8,34]. The TIBO compound, R82150, does inhibit
two SIVagm strains (SIVagm3 and SIVagmTYO-1) and
weakly inhibits SIVmndGB1 [45]. This inhibition could
be due to the presence of aromatic amino acid residues at
positions 181 (tyrosine in SIVmnd) and 188 (tryptophan
in SIVagm and phenylalanine in SIVmnd) (Fig. 5). A
new lentivirus identified in wild chimpanzees, SIVcpz, is
more closely related to HIV-1 [43]. The RTs of SIVcpz
and HIV-1 exhibit 85% identity at the amino acid
sequence level. In the non-nucleoside inhibitor-binding
pocket, only one residue difference exists, at position 179
(valine in HIV-1 RT; threonine in SIVcpz RT) (Fig. 5).
This suggests that the RT of SIVcpz should have a
hydrophobic pocket that is quite similar to that of HIV-1
RT. We would predict that the SIVcpz RT will be sensi-
tive to at least some non-nucleoside inhibitors.
Comparisons of HIV-1 RT/a-APA structure with HIV-1
RT/DNA/Fab structure
The RT/ot-APA structure is more similar to the
RT/nevirapine structure [15] than to the RT/DNA/Fab
[16], the unliganded RT [20] and the RT/Fab (R Raag,
et al., & E Arnold, abstract B03, p. 44, American Crystal-
lographic Association Meeting, Atlanta, June, 1994)
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structures. Superposition of the Ca coordinates of the
RT/o-APA and the RT/nevirapine structures revealed
few differences in the overall trace and the folding of sec-
ondary-structure elements. Superposition of the Cot
coordinates of unliganded RT and the RT/DNA/Fab
complex showed that the individual subdomains in both
structures have comparable positions except for the p6 6
thumb. Conversely, superposition of the Cot backbones
of RT in the RT/o-APA and RT/DNA/Fab complexes
revealed not only numerous local conformational
changes in the vicinity of the non-nucleoside inhibitor-
binding pocket, but also significant global conforma-
tional changes in the p66/p51 heterodimer. Comparisons
of unliganded RT versus the RT/DNA/Fab complex,
and of unliganded RT versus the RT/nevirapine complex
have been described [20]. Jager et al. [19] have presented
an interesting analysis of the relationship between the
RT/nevirapine and RT/DNA/Fab complexes and
described a swivel motion between the p66 fingers and
palm subdomains and the other subdomains. The current
comparison of the RT/oa-APA and RT/DNA/Fab struc-
tures has revealed, in addition, that groups of subdomains
appear to move in a coordinated fashion relative to the
p66 fingers and palm subdomains.
Global conformational differences
Superposition analysis of the p66/p51 heterodimer in the
RT/o-APA and RT/DNA/Fab structures revealed that
RT could be divided into four large superimposable
regions that correspond to groups of subdomains
(R1-R4) (Table 5; Fig. 6). Smaller fragments not
included in these regions are those that adopt different
conformations in the two complexes and the relatively
disordered regions. The results of the superposition
analysis are summarized in Table 5.
The heterodimer interface seems not to be an inherent
boundary between the superimposable regions. R2 and
R3 contain subdomains from both p66 and p51 and the
relative movements between subdomains that contact
each other across the heterodimer interface are small
compared with those between subdomains of the same
subunit. Interestingly, both R2 and R3 in the RT/
DNA/Fab complex are positioned closer to the DNA-
binding cleft than in the RT/at-APA complex. Thus, rel-
ative to the DNA-binding cleft in the RT/DNA/Fab
complex, the binding cleft in the RT/a-APA complex is
expanded by -5 A at the tip of the thumb subdomain.
This may reflect rearrangements of the heterodimer upon
DNA binding, owing to the interactions between the
DNA and the polymerase and RNase H domains. In
addition, interactions between ot-APA and structural ele-
ments at the base of the thumb may widen the cleft
(Fig. 7) by forcing a separation between regions R1 and
R2. Modification of the cleft width by binding of non-
nucleoside inhibitors may affect binding or translocation
of the dsDNA template-primer [46].
In unliganded HIV-1 RT structures, the p66 thumb sub-
domain folds into the DNA-binding cleft (R Raag, et al.,
& E Arnold, abstract B03, p. 44, American Crystallo-
graphic Association Meeting, Atlanta, June, 1994; [20]).
This movement is independent of the movements of the
rest of the heterodimer and, therefore, is different from
the movement of the p66 thumb observed here. In the
present comparison, the p66 thumb and connection sub-
domains, and the p51 fingers subdomain (R2) constitute
one movable entity. Thus, the widening of the DNA-
binding cleft observed in the RT/ot-APA structure can-
not be accounted for by the independent 'up and down'
motions of the thumb, but instead must result from rela-
tive movements of regions R1 and R2.
The independent movement of region R3 may be
related to its role in crystal packing. In all reported crystal
structures of HIV-1 RT [15,16,19,20], including the
RT/(x-APA complex, and the isolated RNase H domain
[47,48] structures, the five-stranded 3-sheet of one
RNase H subdomain interacts with the five-stranded
3-sheet of another two-fold-related RNase H domain to
form an intermolecular 10-stranded 3-sheet. Because
this crystal-packing interaction has been observed in
every crystalline form of HIV-i RT (C2, P3,12 and
F222) and HIV-1 RNase H reported so far, it may repre-
sent a favorable crystal-packing motif. It is not known
whether this two-fold crystal-packing interaction is of
biological significance.
It is unclear whether some or all of these conformational
rearrangements result from differences in crystal packing
in different crystalline forms or from template-primer
and/or inhibitor binding, or a combination of causes.
Additional structures of HIV-1 RT, for example, in com-
plex with both nucleic acid and a non-nucleoside
inhibitor, may help identify the potential causes of the
observed conformational changes. Regardless of the
cause, however, it appears that HIV-1 RT is a flexible
enzyme that contains several regions capable of moving
Table 5. Analysis of the global conformational changes of the HIV-1 RT
p66 /p51 heterodimer between the HIV-1 RT/o-APA and the HIV-1
RT/DNA/Fab structures.
Subdomains Number Rms Rotation Translation
Regiona included of atoms deviation (A) (A
R1 p66 fingers 191 1.2 0.0 0.0
p66 palm
R2 p66 thumb 234 1.3 5.5 1.6
p66 connection
p51 fingers
R3 RNase H 178 1.0 19.0 0.9
p51 thumb
R4 p51 palm 175 1.1 17.8 1.0
p51 connection
aResidues included in each region are listed as follows: R1 p66 (1-25, 27-50.
52-65, 77-89, 95-111, 113-134, 140-184, 186 193, 196-218); R2 p66 (252-
285, 292-312, 321-356, 362-402, 408-427), p51 (20-42, 47-50, 55-63, 70-
80, 115-122, 124-150); R3 p66 (428-555), p51 (252-271, 280-283, 285-296,
301-314); R4 p51 (93-97, 103-114, 151-159, 161-219, 232 357, 362-417,
419-425).
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Fig. 6. Global conformational differ-
ences between the RT/a-APA and the
RT/DNA/Fab complexes. (a) Colored
ribbons of the p66/p51 heterodimer in
the RT/ci-APA structure showing the
superimposable regions between the
RT/ao-APA and the RT/DNA/Fab com-
plexes. Regions that superimpose well
(RI-R4) are labeled in correspondence
with Table 5. Regions that do not super-
impose well are depicted as C traces.
The black dashed line corresponds to
the heterodimer interface between the
p66 and p51 subunits. To obtain the
best view of the regions observed to
move concertedly, the view shown is
rotated by -30 ° along both a vertical
axis and the axis perpendicular to the
plane of the page relative to the orienta-
tion shown in Fig. 3. (b) Vector diagram
showing the direction of movement of
the superimposable regions between the
RT/ax-APA and the RT/DNA/Fab com-
plexes. The view is the same as in (a).
The vectors correspond to average Ca
displacements between superimposable
regions in the two structures when the
heterodimers are aligned on the basis of
the R1 superposition (the p66 fingers
and palm subdomains). The vectors rep-
resent the magnitude and direction of
movement for the transformation of
each region from the RT/ca-APA com-
plex to its counterpart in the
RT/DNA/Fab complex. The coordinate
axes are shown in thinner lines and are
labeled x, y and z.
relative to one another. This is also reflected in the asym-
metry of the heterodimer, whose subdomains are folded
similarly but are packed quite differently in the p66 and
p51 subunits. The biological significance of this flexibil-
ity is unclear. However, we suggest that flexibility may be
required for the enzyme's multiple functions. If template-
primer binding induces conformational changes
throughout the heterodimer, this could provide a means
of allosteric communication between separated regions of
the enzyme, for example, between the polymerase and
RNaseH active sites, during the potentially coupled
processes of dNTP incorporation and RNA-template
degradation. Inhibition by non-nucleoside compounds
may also be explained in terms of allosteric control of
dNTP incorporation, through interactions with nearby
amino acid residues that may induce conformational
changes at the polymerase active site.
Local conformational differences near the non-nucleoside
inhibitor-binding pocket
There are marked differences in the side-chain orienta-
tions of Tyrl81 and Tyr188 in the presence and absence
of non-nucleoside inhibitor. In the RT/DNA/Fab and
unliganded RT structures, the side chains of Tyr181 and
Tyr188 in p66 both point away from the polymerase
active site and towards the hydrophobic core. In the
RT/ot-APA and RT/nevirapine structures, these two
residues have their side chains pointing towards the poly-
merase active site, creating space in the pocket to accom-
modate the inhibitor. Moreover, in the structure of the
RT/ot-APA complex, the side chain of Tyrl81 is in a
position that pushes Trp229 away from its position in the
RT/DNA/Fab complex, which may be partly responsi-
ble for the conformational change of the 12-313-14
sheet (see below). The connecting loop of the 9-310
hairpin in p66 is folded differently in the RT/a-APA
and the RT/DNA/Fab structures (Fig. 7). When the
core portion of the palm subdomains of the two struc-
tures (otE-39-310--xF) are superimposed, the overall
rms fit of 60 Cot atoms is 0.99 A. However, the Cot posi-
tions for the YMDD motif (183-186) differ by 0.9 A,
2.2 A, 3.2 A and 0.9 A, respectively. The conformations
of the YMDD motif of the p51 subunit in these two
structures are more similar to that of the p66 subunit in
the RT/ao-APA structure than to that of the
RT/DNA/Fab p66 subunit. The YMDD motifs of both
p66 and p51 in the structures of unliganded RT and the
RT/nevirapine complex adopt conformations that are
quite similar to that in the p66 subunit in the RT/
a-APA structure (data not shown). It seems plausible
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Fig. 7. Stereoview. of the superposition
of the RT/ac-APA (thick lines) and the
RT/DNA/Fab (thin lines) structures,
showing only the p66 palm and thumb
subdomains. The DNA shown corre-
sponds to a portion of the model in the
RT/DNA/Fab complex. The view is
down the DNA axis from the RNase H
domain. The superposition is based on
the p66 fingers and palm subdomains
(R1, Table 5). The thumb subdomain in
the RT/ca-APA complex is positioned fur-
ther away from the DNA-binding cleft
compared with the thumb in the
RT/DNA/Fab complex. The side chains
of Tyr181 and Tyr188 in the RT/a-APA
complex (thick lines) rotate away from
the positions in the RT/DNA/Fab com-
plex (thin lines) and point towards the
polymerase active site, thus, creating
space for binding non-nucleoside
inhibitors.
that the conformational difference of the YMDD motif
observed in the p66 subunit of the RT/DNA/Fab com-
plex relative to its conformation in other structures may
be caused by binding of the template-primer. The pre-
cise conformation and mobility of this catalytically
essential region may play an important role in the mech-
anism of non-nucleoside inhibition (see below).
Significant conformational changes in the 1312-[313-314
sheet of the p66 palm subdomain were observed in the
RT/oa-APA structure relative to the RT/DNA/Fab struc-
ture and may be a result of binding oL-APA because there
are several close contacts between ot-APA and this 3-sheet
(Table 3). The 312-1313 hairpin has been denoted the
'primer grip' because of its close interactions with the
3'-terminus of the primer strand. This segment forms part
of the non-nucleoside inhibitor-binding pocket. Site-
directed mutagenesis studies indicated that modification
of these residues can have significant effects on the poly-
merase activity ([49]; P Boyer, personal communication).
In the RT/ao-APA structure, movements of 1 lb, the
311b- 12 loop, and the 1312-1313 hairpin relative to their
positions in the RT/DNA/Fab structure result in expan-
sion of the non-nucleoside inhibitor-binding pocket
(Fig. 7). The 1313-314 loop, which contains Pro236, is
pulled towards the bound inhibitor. This yields a differen-
tial twisting of the 314 strand out of the plane of the
1-sheet. The binding of the non-nucleoside inhibitor de-
forms the primer grip of the p66 palm subdomain. Alter-
natively, these conformational changes may be associated
with the coordinated movements of the p66 thumb and
connection subdomains discussed in the previous section.
Implications of the HIV-1 RT/ot-APA structure for
mechanisms of non-nucleoside inhibition of HIV-1 RT
Numerous lines of evidence suggest that conformational
mobility may be required during DNA polymerization
by HIV-1 RT and other polymerases. The accumulated
structural and biochemical evidence shows that oL-APA,
nevirapine and other non-nucleoside inhibitors bind at
similar locations in HIV-1 RT. A preliminary comparison
of the RT/o-APA, RT/TIBO (K Das, et al., unpub-
lished data) and RT/nevirapine [15,17] structures
revealed striking similarity in the binding modes of these
diverse non-nucleoside inhibitors and remarkable consis-
tency of a butterfly-like shape adopted by the inhibitor
molecules Ding et al., unpublished data). In their
description of the structure of a complex of HIV-1 RT
with nevirapine, Kohlstaedt et al. [15] postulated that the
non-nucleoside inhibitor may be working either by alter-
ing the precise geometry of the polymerase active site, or
by restricting the mobility of the p66 thumb subdomain.
Whatever the mechanism of inhibition, it is likely to be
similar for the various non-nucleoside inhibitors.
One possible mechanism of inhibition of HIV-1 RT by
non-nucleoside inhibitors could be that the conforma-
tional changes in the inhibitor-binding pocket distort the
precise geometry and/or mobility of the nearby poly-
merase active site. During DNA polymerization, the
polymerase catalytic site may need conformational flexi-
bility in order to interact with the constantly changing
template-primer substrates, distinguish different dNTP
substrates, and permit translocation of the template-
primer following nucleotide incorporation. Comparison
of the RT/ot-APA and RT/DNA/Fab structures suggests
that binding of non-nucleoside inhibitors may keep the
side chains of Tyr181 and Tyr188 rotated away from the
pocket and towards the polymerase active site. This
change, or some of the other conformational changes
observed in the immediate vicinity of the binding
pocket, could affect the mobility of some key elements of
the nearby polymerase active site, including the YMDD
motif, which is in a different conformation in the
inhibitor-bound and DNA-bound structures (discussed
above). As a consequence, the polymerase active site may
no longer be able to deform its geometry to interact with
the template-primer or to adjust to a conformation
favorable for efficient catalysis. It is important to note
that binding of non-nucleoside inhibitors to HIV-1 RT
does not markedly decrease binding of template-primer
or dNTP substrates [8,34,35].
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In an alternative scenario for the mechanism of inhibi-
tion, the non-nucleoside inhibitor-binding pocket may
function as a hinge between the palm and the thumb
subdomains (Fig. 7) and the binding of a non-nucleoside
inhibitor could distort the conformation of the primer
grip of the palm subdomain and restrict the mobility of
the thumb subdomain. The binding of the non-nucleo-
side inhibitor changes the conformation of the
1312-1313-314 sheet and the primer grip. Consequently,
the distorted primer grip may not be able to interact
with the primer strand and/or function properly in posi-
tioning the primer strand relative to the polymerase
active site. The binding of the non-nucleoside inhibitor
expands the DNA-binding cleft and may restrict the
mobility of the thumb, which could prevent the thumb
from interacting appropriately with the nucleic acid dur-
ing the recognition of the template-primer [16] and, as a
consequence, eliminate the polymerization activity.
Biological implications
One of the most important steps in HIV-1 replica-
tion is the synthesis of double-stranded (ds) DNA
from the viral RNA genome by reverse transcrip-
tase (RT). The only drugs currently used in the
treatment of AIDS are the nucleoside analogs
AZT, ddI, and ddC, which all inhibit RT. The
clinical utility of these drugs is limited by two fac-
tors: serious side effects and the rapid emergence
of drug-resistant mutations in HIV-1 RT. There
are several classes of non-nucleoside inhibitors.
They are highly specific for HIV-1 RT and, there-
fore, are more attractive candidates for clinical use
than the nucleoside analogs. However, they too
encounter drug-resistant viral strains.
The structure of HIV-1 RT in complex with a
non-nucleoside inhibitor, -anilinophenylacet-
amide (-APA) R95845, provides several insights
that may be important in the design of improved
drugs for AIDS treatment. The inhibitor binds in
a hydrophobic pocket lined by a number of aro-
matic side chains that are likely to stabilize the
binding of a non-nucleoside inhibitor, explaining
the observation that non-nucleoside inhibitors
invariably contain at least one aromatic ring. The
mutations that cause high-level resistance to non-
nucleoside inhibitors are located close to the
bound inhibitor, and presumably affect the stabil-
ity of inhibitor binding.
Comparison of the structure of HIV-1 RT bound
to 0a-APA with that of HIV-1 RT bound to
dsDNA/Fab shows significant changes in the local
environment of the inhibitor-binding pocket,
including rotations of the side chains of Tyrl81
and Tyr188 out of the pocket and movements of a
hinge-like structure consisting of two -sheets of
the p66 palm subdomain. There are also changes
in the overall structure of the protein: several
rigid-body rearrangements of subdomains, por-
tions of subdomains, or groups of subdomains
were observed. These mobile portions of the
structure may be required to move in a coordi-
nated fashion during DNA polymerization.
We propose that the binding of non-nucleoside
inhibitors may distort the geometry, or restrict
the mobility, of the polymerase active site, which
is close to the inhibitor-binding pocket, and that
the effects on the three catalytically essential
aspartic acid residues (Asp1lO, Asp185 and
Asp186) may be especially important. Alterna-
tively, the inhibitor-binding site may act as a
hinge between the palm and the thumb subdo-
mains, which may move relative to each other
during polymerization, and this movement may
be prevented by inhibitor binding. Because the
hairpin structure formed by -strands 12 and 13,
which functions as a 'primer grip', is also part of
the inhibitor-binding pocket, the proper position-
ing of the primer terminus at the active site may
also be affected by inhibitor binding.
Materials and methods
Protein and inhibitor preparation and crystallization
The samples of HIV-1 RT used in crystallization were prepared
as described in [50]. Crystals were grown using conditions [51]
modified from those reported by Kohlstaedt et al. [15] for crys-
tallization of a complex of HIV-1 RT with nevirapine. The
mixing procedure was designed to enhance inhibitor solubility
and availability upon mixing with concentrated HIV-1 RT
solution. A 20 mM stock solution of the non-nucleoside
o-APA inhibitor R95845 was prepared by dissolving it in
dimethylsulfoxide (DMSO). A 15 mM working solution of
ct-APA containing 5% 13-D-octylglucopyranoside (-OG) was
then prepared by adding the appropriate volume of 20% (w/v)
3-OG to the 20 mM stock solution and mixing thoroughly.
The purified HIV-1 RT enzyme was concentrated and trans-
ferred into a buffer of 10 mM Tris-HCl (pH 8.0), 75 mM NaCl
using Centricon-30 microconcentrators (Amicon), yielding a
solution with an HIV-1 RT concentration of 40-45 mg ml-'.
The concentrate was used immediately or divided into 2.5 mg
aliquots and frozen at -20 0C for future use. Thawed aliquot(s)
of HIV-1 RT concentrate were kept on ice and then quickly
mixed by vortexing with the working solution at a 2:1 molar
ratio of inhibitor to HIV-1 RT and kept on ice for 15 min.
Crystallization was performed using the hanging-drop vapor-
diffusion method at 4C using a crystallization solution com-
posed of 50 mM Bis-Tris propane (pH 6.8), 100 mM
(NH4)2S04, 10% glycerol and 12% (w/v) polyethyleneglycol
(PEG) 8000. The hanging drops were prepared by adding equal
volumes (5 R±l) of the crystallization solution to the concen-
trated protein solution and mixing thoroughly to give a final
protein concentration in the drop of 19-20 mg ml- l . The initial
precipitation observed in the drops upon mixing the HIV-I
RT with the crystallization solution dissipated after 6-10 h at
4°C. Crystals began to appear 24 h after drop preparation and
reached a size of 1.5 mmx0.3 mmx0.2 mm after -7 days at
4°C. The crystals often resembled knife-blades or arrowheads in
appearance and belonged to the monoclinic space group C2
with cell dimensions of a=223.3 A b=69.9 A, c=106.5 A, and
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[3=105.4 °, which are close to these reported for the apparently
isomorphous crystals of the HIV-1 RT/nevirapine complex
[15]. One asymmetric unit contains one HIV-1 RT p66/p51
heterodimer and one o-APA inhibitor with a total molecular
weight of 117 kDa, corresponding to a specific volume VM of
3.42 A3 Da-1, and a solvent content of 64% by volume,
assuming that the standard partial specific volume for protein is
0.74 ml g.
For preparation of the tetrakis(acetoxymercuri)methane
(TAMM, Strem Chemicals) heavy-atom derivative, crystals
were first rinsed for 5-10 s in crystallization solution and then
soaked in crystallization solution plus 5 mM TAMM and
0.5 mM ot-APA inhibitor R95845 for 20-27 h followed by
mounting. For the preparation of the 5-mercurideoxyuridine
5'-triphosphate (Hg-dUTP, Sigma) heavy-atom derivative,
crystals were rinsed for 5-10 s in crystallization solution and
then soaked in crystallization solution plus 2 mM dithiothreitol
and 0.5 mM ot-APA inhibitor R95845 for 4-4.5 h. Crystals
were subsequently rinsed twice (briefly) in crystallization solu-
tion and back-soaked for 2.5 h in crystallization solution plus
0.5 mM ox-APA inhibitor R95845. Crystals were finally soaked
in crystallization solution plus 3 mM Hg-dUTP and 0.5 mM
ot-APA inhibitor R95845 for 12-15 h and then mounted.
X-ray data collection
Crystals used for X-ray data collection had a typical size of
1.2 mmx0.3 mmX0.2 mm. The X-ray diffraction data were
measured at the Cornell High Energy Synchrotron Source
(CHESS) using the highly intense F1 beamline. The diffraction
data were collected at -15°C using 1.5-2.0° oscillations from
morphologically oriented crystals and recorded on Fuji storage
phosphor image plates with a crystal-to-image plate distance of
30 cm. The X-ray wavelength used was =0.91 A and the
beam was limited using a 0.3 mm collimator. Exposure times
were usually 6-12 s. The image plates were scanned using a
BAS2000 Fuji storage phosphor scanner with a raster step of
100 [Lm. The digitized data were processed, merged, and
scaled together from multiple crystals using a modified version
of the Purdue oscillation film processing package, MTOPS,
(G Kamer and E Arnold, unpublished program). Two native
datasets were collected (Table 1): one dataset is for HIV-1 RT
in complex with the dibrominated ot-APA compound
R95845; the other is for HIV-1 RT in complex with
R90385, the dichlorinated analog of R95845. Because the
dibrominated native dataset is relatively more complete and has
slightly higher quality, the structure determination and refine-
ment reported here is principally based on this dataset. Two
heavy-atom derivative datasets of the HIV-1 RT/ot-APA
R95845 complex were also collected (Table 1) and were
scaled to the dibrominated native dataset using mean local scal-
ing by. resolution ranges [52].
Structure determination
The crystal structure of the HIV-I RT/a-APA complex was
determined using the molecular replacement (MR) method as
implemented in the program X-PLOR [22]. Since the struc-
ture of the HIV-1 RT/DNA/Fab complex was solved [16]
and refined to 2.8 A resolution (J Ding et al., unpublished
data), the initial experiments tried to use either full or poly-
alanine models of the HIV-1 RT p66/p51 heterodimer from
the HIV-1 RT/DNA/Fab complex as starting models for mol-
ecular replacement. However, the rotation function search and
subsequent Patterson correlation (PC) refinement [53] of 6000
highest rotation function search peaks revealed no outstanding
solutions. Preliminary comparison of the RT/DNA/Fab
complex and the RT/nevirapine complex had indicated that
the relative orientations and positions of the RT subdomains in
the two structures have some substantial differences [18], that
may account for the failure of the rotation function search
described above. Therefore, a new starting model was built
that consisted of a partial polyalanine model of RT from the
RT/DNA/Fab complex (PDB entry HMI) [16] (J Ding et al.,
unpublished data), where the partial C model from the
RT/nevirapine complex [15] was used as a guide for backbone
position (PDB entry 1HVT). This model contained 937 amino
acid residues and 4660 non-hydrogen atoms. Most of the con-
necting loops, which were missing in the original RT/nevirap-
ine structure, were built based on the RT/DNA/Fab structure
with the exception of residues 225-233 and 244-255 in p66
and 230-250 in p51. The rotation function search using dif-
fraction data between 10.0 A and 4.0 A resolution and the sub-
sequent PC refinement revealed a single solution at (,, =
(0.0,0.0,0.0) which is 8a higher than the next peak. The ensu-
ing translation function search also yielded a single peak at
(0.004,0.0,0.004), which is 1 1(r higher than the second peak.
Rigid-body refinement of the partial polyalanine model in
which the model was divided into five pieces yielded an
R-factor of 0.44, and 20 cycles of positional refinement using
conjugate-gradient minimization reduced the R-factor further
to 0.41 for reflections between 10.0 A and 3.0 A resolution.
Isomorphous difference Fourier syntheses for the two
heavy-atom derivatives using the MR phases revealed two sites
of mercury binding at Cys38 in both the p66 and the p51 sub-
units, which are the same binding positions as in the
RT/DNA/Fab complex Ding et al., unpublished data) and
confirmed that the MR solution was correct. These heavy-
atom sites for the two isomorphous derivatives were also inde-
pendently verified using both minimum and sum functions in
the Patterson vector search program VMAP (R Williams and E
Arnold, unpublished program). The MR phasing was then
supplemented by MIR phasing, solvent flattening and phase
extension. The phases were improved with the approach of
iterative combination of the partial model and the initial MIR
phases using the program PHASES (W Furey, and S Swami-
nathan, abstract PA33, p.73, American Crystallographic Associ-
ation Meeting, New Orleans, April, 1990).
Model building and structure refinement
Iterative molecular modeling was performed using the graphics
program 'O' [23]. Residue assignment and side chain place-
ment were guided by difference Fourier maps with various
coefficients, and omit electron-density maps (both conven-
tional and simulated-annealing omit maps). The refinement of
the structure was carried out using the molecular dynamics
technique in the program X-PLOR [22]. At early stages, the
refinement was carried out using the conventional positional
refinement protocol to avoid the movement of main-chain
atoms into the side-chain densities. The simulated-annealing
protocol was employed when most of the side chains had been
placed correctly. In the omitted regions of the model, the miss-
ing amino acid residues were gradually (usually one or two
residues per cycle) inserted from both ends of the polypeptide
chains if there was clear electron density for the new residues.
During the process of structure determination, several diffrac-
tion datasets were also collected for crystals of other HIV-1
RT/non-nucleoside inhibitor complexes that belong to the
same space group, and initial structures were determined based
on the HIV-1 RT/a-APA structure. The unit cell dimensions
for these different complexes are related but have significant
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differences, indicating incomplete isomorphism. Thus, the
technique of averaging electron density from multiple crystal
forms of different HIV-1 RT/inhibitor complexes was applied
using the CCP4 package [25] and RAVE [54]. The structures
used in the multiple crystal form map averaging procedure are
primarily the HIV-1 RT/a-APA complex, the HIV-1
RT/TIBO R86183 complex (a=227.9 A, b=70.3 A,
c=106.0 A, 3=105.50) (K Das et al., unpublished data), and the
HIV-1 RT/BHAP U-90152 complex (a=227.5 A, b=69.8 A,
c=106.1 A, 13=105.70) (W Zhang et al., unpublished data).
Each crystal form was initially modeled by breaking the
p66/p51 heterodimer into 13 segments according to individual
subdomains which were positioned and oriented using rigid-
body refinement. The map averaging was initially carried out
at 3.5 A resolution and then gradually extended to 3.0 A reso-
lution while increasing resolution in steps of 0.02 A.
The multiple crystal form map averaging yielded the best qual-
ity maps, which resolved many ambiguities and showed dra-
matically improved electron density for many side chains in the
regions where there was weak or no density in any previous
maps. Therefore, in the later stages of model building, we used
averaged maps of multiple crystal forms of HIV-1
RT/inhibitor complexes with difference Fourier maps as well
as omit maps as references. Computation of the free R-factor
[55] after each cycle of refinement was also performed to mon-
itor the progress and the quality of the model. A subset of 1258
reflections, corresponding to 4% of the observed unique reflec-
tions, was randomly selected as the test dataset for evaluation of
the free R-factor. At the final stages of structure refinement,
the newly released full model of the HIV-1 RT/nevirapine
complex (PDB entry 3HVT) and the coordinates of an unli-
ganded HIV-1 RT structure [20] were used as references for
model building. This was especially valuable in resolving the
ambiguity of backbone tracing in some regions with poor elec-
tron density and in the placement of some side chains.
The location of the non-nucleoside inhibitor was initially
revealed by difference Fourier calculations. After several cycles
of refinement and successive model building, the difference
Fourier electron-density maps clearly indicated significant posi-
tive density in the non-nucleoside inhibitor-binding pocket.
However, the initial difference Fourier density was not of suffi-
cient quality to uniquely determine the orientation and confor-
mation of the inhibitor. This led to an initial misinterpretation
of the inhibitor orientation which was subsequently corrected
as the phases and map quality improved. As two separate
datasets were collected for HIV-1 RT complexes: one with
dibrominated ot-APA inhibitor R95845 and the other with
dichlorinated Oa-APA inhibitor R 90385, it was anticipated that
the difference Fourier calculation between these two com-
plexes would reveal the two bromine positions, which would
facilitate assignment of the precise position and conformation
of the Ot-APA inhibitor. The difference Fourier maps between
the HIV-1 RT/R95845 complex and the HIV-1
RT/R90385 complex revealed two significantly higher peaks
which were located in the non-nucleoside inhibitor-binding
pocket and were attributed to the two bromine atoms (Fig. 2a).
As the refinement and modeling continued, the electron den-
sity for the whole Oa-APA compound became clearer. The
a-APA inhibitor was included in the structure refinement only
after the difference electron density of Ot-APA was well
resolved and its orientation was unambiguous (Fig. 2a). The
orientation of the primary amide group of (x-APA was assigned
based on plausible hydrogen bonds of the amide nitrogen atom
with the carbonyl oxygen atoms of Tyr188 and Val189.
Alternative orientations of this group are possible and cannot
be ruled out by the current analysis.
The refinement of the current model, including 7815 non-
hydrogen atoms, has converged to an R-factor of 0.255 for
30 186 reflections and a free R-factor of 0.360 for 1258 reflec-
tions between 10.0 A and 2.8 A resolution (81.8% complete to
2.8 A). Fig. 2b shows a representative portion of a 2mFo-Fc
Fourier electron-density map at 2.8 A resolution in the region
around the non-nucleoside inhibitor-binding pocket. A sum-
mary of the current model and corresponding refinement sta-
tistics is given in Table 2. The loops 3-14 (65-72), and
17-138 (133-143), the region 314-oxH (249-258), the aoI--J
loop (281-293), and the C-terminal 15 residues of p66, as well
as 31 lb and 1312 (218-230) of p51 are highly disordered with
very poor electron density. The backbone trace in these
regions is therefore only tentatively assigned. Due to the very
weak or invisible electron density for the side chains, the fol-
lowing residues have been modeled as alanines during the
refinement: p66 - 36, 66, 71, 72, 134-139, 218-223, 249,
263, 281-293, 297-302, 311, 312, 323, 356-358, 366, 451,
556-558; and p51 - 13, 22, 70, 113, 121, 197, 199, 218-220,
224-230, 253, 270, 278, 281, 305, 356-358, 361-363. At the
current stage of refinement, water molecules have not been
included. However, there are clear indications that, through-
out the electron-density maps, some residual electron densities
exist at a 2-3(r level that have reasonable stereochemistry to be
water molecules. All atoms were refined with full occupancy.
A single overall temperature factor was refined at the early
stages of refinement and converged to a value of -43 A2,
which is a little higher than the B-factor deduced from the
Wilson plot (B=37 A2). At the final stages of refinement,
restrained individual isotropic B-factors were refined, which
decreased both the R-factor and the free R-factor by -1.5%.
The regions with the highest B-factors are surface regions
exposed to solvent, especially the fingers and thumb subdo-
mains of p66 and the thumb subdomain of p51. The mean
error in atomic positions was estimated by the method of Luz-
zati [56] to be 0.42 A. The stereochemistry of the model has
been examined using the programs X-PLOR [22] and
PROCHECK [57]. The analysis of main-chain conformation
shows that 79.4% of residues lie in the most favored regions
and no residues are found in disallowed regions of the
Ramachandran plot.
Analysis of conformational differences between the HIV- I
RT/ot-APA complex and the HIV- RT/DNA/Fab complex
The analysis was 'performed using the least-squares routines
Isq_explicit and Isqimprove in the program 'O' [23]. A least-
squares superposition of all Caot atoms in the p66/p51 het-
erodimer in the RT/a-APA and RT/DNA/Fab structures
yielded an rms deviation of 3.5 A for 982 atoms. To achieve
better superpositions, we broke the p66/p51 heterodimer into
superimposable regions using the following strategy. First,
superpositions were carried out for each individual subdomain.
Portions outside each superimposed subdomain were then ana-
lyzed to locate fragments containing four or more sequential
Cot atoms that were within a distance cutoff of 1.9 A when
superimposed. This analysis resulted in new transformations for
groups of fragments that superimposed similarly throughout the
p66/p51 heterodimer. Based on the new transformations, a
second cycle of superposition analysis was performed with a
distance cutoff of 2.5 A to locate larger superimposable regions.
This procedure identified four large superimposable regions in
the size range 175-234 Ca atoms for the whole p66/p51 het-
erodimer (Fig. 6; Table 5). Each of these regions in the two
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structures can be superimposed with an rms deviation of
<1.3 A. Table 5 gives the rotational and translational parame-
ters which were used to superimpose the individual regions of
the RT/ot-APA structure onto their counterparts in the
RT/DNA/Fab structure when the heterodimers were aligned
on the basis of the R1I superposition (the p66 fingers and palm
subdomains). The absolute value for the rotation of each
region varies between 5.5 and 19.0 and the translation varies
between 0.9 A and 1.6 A. Regions that could not be readily
superimposed include portions of the inhibitor-binding pocket,
N- and C-terminal portions of polypeptide chains, and the rel-
atively disordered regions.
The coordinates of the HIV-1 RT p66/p51 heterodimer and
the non-hydrogen atom coordinates of the ox-APA inhibitor
R95845 have been deposited with the Brookhaven Protein
Data Bank for immediate release (entry number IHNI).
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